Now showing items 1-1 of 1

    • Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. 

      Sternberg, C; Armstrong, A; Pili, R; Ng, S; Huddart, R; Agarwal, N; Khvorostenko, D; Lyulko, O; Brize, A; Vogelzang, N; Delva, R; Harza, M; Thanos, A; James, N; Werbrouck, P; Bögemann, M; Hutson, T; Milecki, P; Chowdhury, S; Gallardo, E; Schwartsmann, G; Pouget, J-C; Baton, F; Nederman, T; Tuvesson, H; Carducci, M (2016-08)
      Purpose Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improved progression-free survival (PFS) in a randomized, placebo-controlled phase II trial in men with metastatic castration-resistant ...